Computer 'redesigned' antibodies to fight HIV

Computer-redesigned antibodies may speed the search for an effective therapy or vaccine for a virus that so far has eluded all attempts to eradicate it

<a href="http://www.shutterstock.com/pic-135725843/stock-photo-aids-awareness-red-ribbon-isolated-on-black-with-aids-word.html" target="_blank">HIV/AIDS</a> image via Shutterstock
Press Trust of India Washington
Last Updated : May 20 2015 | 12:56 PM IST
Scientists have used a computer programme to "redesign" an antibody which is highly potent and can neutralise more strains of the AIDS-causing human immunodeficiency virus (HIV) than any known natural antibody.

The findings suggest that computer-redesigned antibodies may speed the search for an effective therapy or vaccine for a virus that so far has eluded all attempts to eradicate it.

"There's a consensus (in the HIV field) that the vaccine that works is going to be a designed one," said James Crowe, from the Vanderbilt University Vaccine Centre who led the work.

ALSO READ: Cipla among winners in $860 million S Africa aids drug tender

Working with colleagues at The Scripps Research Institute in California, the researchers began with a "parent" antibody isolated from the blood of an HIV-infected person that was a strong "neutraliser" of HIV in laboratory tests.

The researchers then used the Rosetta computer programme, which can predict the structure of a protein from its amino acid sequence, to "redesign" the antibody.

By changing a single amino acid, they were able to increase the stability of the antibody when it bound to HIV's envelope protein.

The researchers did not change the interface between the antibody and the virus. Rather, by increasing its thermodynamic stability, the antibody became more rigid and better able to fit the HIV protein like a lock and key.

"By changing a single amino acid, we made it four times more potent, four times stronger and it also started killing even more HIV strains than the parent antibody," said Crowe.

The original, isolated antibody is now being produced in great quantities from a single clone of immune cells, and thus is a "monoclonal" antibody.

It currently is being tested in clinical trials. Crowe said the redesigned antibody could be added to the study as a second-generation version.

The field of redesigning antibodies has grown quickly out of the need to treat and prevent debilitating and often-fatal viral infections, and from technological advances that have made it possible to "see" and strengthen the interactions between virus and virus-killing antibodies.

HIV evolves every day, or alters the envelope protein on its surface to evade immune detection, researchers said.

The research was published in The Journal of Clinical Investigation.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 20 2015 | 12:22 PM IST

Next Story